©The Author(s) 2015.
World J Crit Care Med. May 4, 2015; 4(2): 139-151
Published online May 4, 2015. doi: 10.5492/wjccm.v4.i2.139
Published online May 4, 2015. doi: 10.5492/wjccm.v4.i2.139
Table 11 Pharmacokinetic and physicochemical properties of drugs commonly used in the intensive care units1
| Indication/class | Specific drug | LogP | Pb (%) | Vd (L/kg) |
| Sedative | ||||
| Propofol | 4.16 | 98 | 60 | |
| Midazolam | 3.33 | 97 | 2 | |
| Lorazepam | 3.53 | 91 | 1.3 | |
| Dexmedetomidine | 3.39 | 94 | 1.3 | |
| Analgesic | ||||
| Morphine | 0.9 | 35 | 3 | |
| Fentanyl | 3.82 | 83 | 5 | |
| Hydromorphone | 1.62 | 20 | 1.2 | |
| Delirium | ||||
| Quetiapine | 2.81 | 83 | 10 | |
| Haloperidol | 3.66 | 92 | 18 | |
| Antiarrhythmic | ||||
| Diltiazem | 2.37 | 80 | 5 | |
| Amiodarone | 7.64 | 98 | 70 | |
| Digoxin | 2.37 | 25 | 6 | |
| Antihypertensive | ||||
| Labetalol | 1.89 | 50 | 5 | |
| Esmolol | 1.82 | 55 | 3 | |
| Hydralazine | 0.75 | 87 | 4 | |
| GI/antiemetic | ||||
| Pantoprazole | 2.18 | 98 | 0.15 | |
| Famotidine | -2 | 18 | 1.2 | |
| Ondansetron | 2.35 | 73 | 2 | |
| Metoclopramide | 1.4 | 30 | 4.4 | |
| Erythromycin | 2.6 | 85 | 0.6 | |
| Anticoagulant | ||||
| Enoxaparin | -8.3 | 80 | 0.07 | |
| Heparin | NA | NA | 0.05 | |
| Fondaparinux | -10 | 94 | 0.1 | |
| Argatroban | -0.97 | 54 | 0.17 | |
| Corticosteroid | ||||
| Methylprednisolone | 1.56 | 78 | 1.1 | |
| Hydrocortisone | 1.28 | 95 | 0.5 | |
| Antifungal/antiviral | ||||
| Voriconazole | 1.82 | 58 | 3 | |
| Fluconazole | 0.56 | 11 | 0.8 | |
| Micafungin | -6.3 | 99 | 0.39 | |
| Amphotericin | -2.3 | 95 | 1.8 | |
| Acyclovir | -1 | 9-33 | 0.6 | |
| Antibiotic | ||||
| Azithromycin | 2.44 | 51 | 0.44 | |
| Aztreonam | -3.1 | 56 | 0.17 | |
| Cefazolin | -1.5 | 80 | 0.14 | |
| Cefepime | -4.3 | 20 | 0.23 | |
| Cefoxitin | 0.29 | 75 | 0.26 | |
| Ceftriaxone | -1.8 | 95 | 0.14 | |
| Ciprofloxacin | -0.81 | 35 | 2.5 | |
| Clindamycin | 1.04 | 93 | 2.5 | |
| Linezolid | 0.64 | 31 | 0.64 | |
| Meropenem | -4.4 | 2 | 0.36 | |
| Metronidazole | -0.46 | 25 | 1 | |
| Moxifloxacin | -0.5 | 50 | 2 | |
| Piperacillin/tazobactam | -0.26 | 0.1 | ||
| Vancomycin | -3.1 | 55 | 0.7 | |
| Anti-seizure | ||||
| Levetiracetam | -0.59 | 8 | 0.6 | |
| Phenytoin | 2.15 | 90 | 0.7 |
- Citation: Erstad BL. Designing drug regimens for special intensive care unit populations. World J Crit Care Med 2015; 4(2): 139-151
- URL: https://www.wjgnet.com/2220-3141/full/v4/i2/139.htm
- DOI: https://dx.doi.org/10.5492/wjccm.v4.i2.139